PMID- 21446938
OWN - NLM
STAT- MEDLINE
DCOM- 20111209
LR  - 20211020
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Print)
IS  - 0041-1132 (Linking)
VI  - 51
IP  - 10
DP  - 2011 Oct
TI  - The Leukocyte Antibody Prevalence Study-II (LAPS-II): a retrospective cohort 
      study of transfusion-related acute lung injury in recipients of 
      high-plasma-volume human leukocyte antigen antibody-positive or -negative 
      components.
PG  - 2078-91
LID - 10.1111/j.1537-2995.2011.03120.x [doi]
AB  - BACKGROUND: We used a multicenter retrospective cohort study design to evaluate 
      whether human leukocyte antigen (HLA) antibody donor screening would reduce the 
      risk of transfusion-related acute lung injury (TRALI) or possible TRALI. STUDY 
      DESIGN AND METHODS: In the Leukocyte Antibody Prevalence Study-II (LAPS-II), we 
      evaluated pulmonary outcomes in recipients of 2596 plasma-rich blood components 
      (transfusable plasma and plateletpheresis) sent to participating hospitals; half 
      of the components were collected from anti-HLA-positive donors (study arm) and 
      half from anti-HLA-negative donors (control arm) matched by sex, parity, and 
      blood center. A staged medical record review process was used. Final recipient 
      diagnosis was based on case review by a blinded expert panel of pulmonary or 
      critical care physicians. RESULTS: TRALI incidence was 0.59% (seven cases) in 
      study arm recipients versus 0.16% (two cases) in control arm recipients for an 
      odds ratio (OR) of 3.6 (95% confidence interval [CI], 0.7-17.4; p = 0.10). For 
      possible TRALI cases (nine study arm, eight control arm), the OR was 1.2 (95% CI, 
      0.4-3.0; p = 0.81), and for TRALI and possible TRALI aggregated together, it was 
      1.7 (95% CI, 0.7-3.7; p = 0.24). Transfusion-associated circulatory overload 
      incidence was identical in the two arms (1.17 and 1.22%, respectively; OR, 1.0; p 
      = 1.0). CONCLUSIONS: TRALI incidence in recipients of anti-HLA-positive 
      components was relatively low for a lookback study (1 in 170) and was higher than 
      in the control arm, but did not reach significance. Based on this trend, the data 
      are consistent with the likelihood that TRALI risk is decreased by selecting 
      high-volume plasma components for transfusion from donors at low risk of having 
      HLA antibodies.
CI  - (c) 2011 American Association of Blood Banks.
FAU - Kleinman, Steven H
AU  - Kleinman SH
AD  - Westat, Inc., Rockville, Maryland, USA. skleinman@shaw.ca
FAU - Triulzi, Darrell J
AU  - Triulzi DJ
FAU - Murphy, Edward L
AU  - Murphy EL
FAU - Carey, Patricia M
AU  - Carey PM
FAU - Gottschall, Jerome L
AU  - Gottschall JL
FAU - Roback, John D
AU  - Roback JD
FAU - Carrick, Danielle
AU  - Carrick D
FAU - Mathew, Sunitha
AU  - Mathew S
FAU - Wright, David J
AU  - Wright DJ
FAU - Cable, Ritchard
AU  - Cable R
FAU - Ness, Paul
AU  - Ness P
FAU - Gajic, Ognjen
AU  - Gajic O
FAU - Hubmayr, Rolf D
AU  - Hubmayr RD
FAU - Looney, Mark R
AU  - Looney MR
FAU - Kakaiya, Ram M
AU  - Kakaiya RM
CN  - National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Study-II
LA  - eng
GR  - N01 HB047172/HB/NHLBI NIH HHS/United States
GR  - N01HB57181/HL/NHLBI NIH HHS/United States
GR  - N01 HB047168/HB/NHLBI NIH HHS/United States
GR  - N01 HB047171/HB/NHLBI NIH HHS/United States
GR  - N01HB47168/HL/NHLBI NIH HHS/United States
GR  - N01 HB047174/HB/NHLBI NIH HHS/United States
GR  - N01 HB047170/HB/NHLBI NIH HHS/United States
GR  - N01 HB047175/HB/NHLBI NIH HHS/United States
GR  - N01 HB047169/HB/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
DEP - 20110329
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Antibodies)
RN  - 0 (HLA Antigens)
SB  - IM
CIN - Transfusion. 2011 Oct;51(10):2054-7. PMID: 21985040
MH  - Acute Lung Injury/epidemiology/*etiology/immunology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies/*blood
MH  - Blood Component Transfusion/*adverse effects/methods
MH  - *Blood Donors
MH  - Cohort Studies
MH  - Female
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Risk
PMC - PMC3606005
MID - NIHMS446415
FIR - Cable, R
IR  - Cable R
FIR - Rios, J
IR  - Rios J
FIR - Benjamin, R
IR  - Benjamin R
FIR - Roback, J D
IR  - Roback JD
FIR - Sacher, R A
IR  - Sacher RA
FIR - Wilkinson, S L
IR  - Wilkinson SL
FIR - Carey, P M
IR  - Carey PM
FIR - Murphy, E L
IR  - Murphy EL
FIR - Custer, B
IR  - Custer B
FIR - Hirschler, N
IR  - Hirschler N
FIR - Triulzi, D
IR  - Triulzi D
FIR - Kakaiya, R
IR  - Kakaiya R
FIR - Kiss, J
IR  - Kiss J
FIR - Gottschall, J
IR  - Gottschall J
FIR - Mast, A
IR  - Mast A
FIR - Schulman, J
IR  - Schulman J
FIR - King, M
IR  - King M
FIR - Nemo, G J
IR  - Nemo GJ
FIR - Glynn, S A
IR  - Glynn SA
FIR - Busch, M P
IR  - Busch MP
FIR - Norris, P
IR  - Norris P
EDAT- 2011/03/31 06:00
MHDA- 2011/12/14 06:00
PMCR- 2013/03/22
CRDT- 2011/03/31 06:00
PHST- 2011/03/31 06:00 [entrez]
PHST- 2011/03/31 06:00 [pubmed]
PHST- 2011/12/14 06:00 [medline]
PHST- 2013/03/22 00:00 [pmc-release]
AID - 10.1111/j.1537-2995.2011.03120.x [doi]
PST - ppublish
SO  - Transfusion. 2011 Oct;51(10):2078-91. doi: 10.1111/j.1537-2995.2011.03120.x. Epub 
      2011 Mar 29.